Biontech stock price as of today’s trading session

As of today’s trading session, BioNTech stock price is hovering around $91.26, showing a moderate uptick of 1.3% intraday, supported by steady trading volumes. Analysts are watching closely as biotech sector momentum remains tied to vaccine pipeline updates and oncology portfolio progress. Technical indicators suggest a short-term resistance near $94. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. For Moderna, investors want to see if sales of its Covid and RSV vaccines can rebound. The company is also seeking FDA approval for an mRNA flu shot. But at this point, the most intense focus is on Moderna's Phase 3 trial for a personalized cancer treatment for melanoma, said RBC Capital Markets analyst Luca Issi. Market watchers voice optimism over the biotech’s late-stage mRNA oncology projects, expecting added value beyond infectious disease applications.